Veradermics (MANE) CEO sells shares under preset trading plan

Rhea-AI Filing Summary

Veradermics, Inc (MANE) reported insider activity by Chief Executive Officer Reid Alexander Waldman. On 2026-08-17 he exercised 3,452 stock options to acquire an equal number of common shares at an exercise price of $12.19 per share from a fully vested option. On the same date, he reported open-market sales totaling 67,500 common shares in multiple tranches at reported weighted-average prices between $106.07 and $111.28 per share, executed pursuant to a Rule 10b5-1 trading plan.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 7 txns

Insider Waldman Reid Alexander

Role Chief Executive Officer

Sold 67,500 shs ($7.28M)

Approx. gross sale proceeds $7.28M

Approx. exercise cost $42K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) F5	3,452	$0.00	$0.00
Exercise	Common Stock	3,452	$12.19	$42K
Sale	Common Stock F1	11,527	$106.72	$1.23M
Sale	Common Stock F2	25,234	$107.53	$2.71M
Sale	Common Stock F3	27,490	$108.45	$2.98M
Sale	Common Stock F4	3,000	$109.38	$328K
Sale	Common Stock	249	$111.28	$28K

Holdings After Transaction: Stock Option (Right to Buy) — 0 shares (Direct); Common Stock — 170,824 shares (Direct)

Footnotes (5)

1. F1. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $106.07 to $107.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
2. F2. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $107.00 to $108.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
3. F3. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $108.00 to $108.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
4. F4. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $109.02 to $109.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
5. F5. This option is fully vested and exercisable as of the date hereof.

Key Figures

Options Exercised: 3,452 shares Exercise Price: $12.19 per share Shares Sold: 67,500 shares +5 more

8 metrics

Options Exercised 3,452 shares Stock Option (Right to Buy) exercised into common stock on 2026-08-17

Exercise Price $12.19 per share Exercise price of stock option converted into 3,452 common shares

Shares Sold 67,500 shares Total common shares sold across reported sale transactions on 2026-08-17

Sale Price Tranche 1 $106.72 per share Weighted-average price for sale of 11,527 common shares (range $106.07–$107.00)

Sale Price Tranche 2 $107.53 per share Weighted-average price for sale of 25,234 common shares (range $107.00–$108.00)

Sale Price Tranche 3 $108.45 per share Weighted-average price for sale of 27,490 common shares (range $108.00–$108.99)

Sale Price Tranche 4 $109.38 per share Weighted-average price for sale of 3,000 common shares (range $109.02–$109.84)

Sale Price Tranche 5 $111.28 per share Price for sale of 249 common shares

Key Terms

Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to Buy), fully vested and exercisable

4 terms

Rule 10b5-1 trading plan regulatory

"transactions were effected under a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported is a weighted average price. These shares were sold"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Stock Option (Right to Buy) financial

"security_title": "Stock Option (Right to Buy)""

fully vested and exercisable financial

"This option is fully vested and exercisable as of the date hereof"

FAQ

What insider transactions did MANE CEO Reid Alexander Waldman report on August 17, 2026?

Reid Alexander Waldman reported exercising 3,452 stock options at an exercise price of $12.19 per share and selling 67,500 common shares in multiple open-market tranches on 2026-08-17, according to the Form 4 for Veradermics, Inc (MANE).

How many Veradermics (MANE) shares did the CEO sell in this Form 4?

The CEO reported open-market sales totaling 67,500 common shares of Veradermics, Inc (MANE). These sales occurred in several tranches on 2026-08-17, with each tranche reported separately in the Form 4 transaction table.

What prices were the MANE shares sold for in the CEO’s August 17, 2026 transactions?

Reported weighted-average sale prices ranged from about $106.72 to $111.28 per share. Footnotes state each tranche was executed through multiple trades within narrower price ranges between $106.07 and $109.84, plus one tranche at $111.28.

Were the Veradermics (MANE) insider sales made under a Rule 10b5-1 trading plan?

Yes. The filing indicates the transactions were effected under a Rule 10b5-1 trading plan. Such plans pre-schedule trades, which can reduce the informational value of the timing of these insider sales for outside investors.

What stock option activity did the MANE CEO report in this Form 4?

He reported exercising a Stock Option (Right to Buy) for 3,452 shares of common stock at an exercise price of $12.19 per share. A footnote states this option was fully vested and exercisable as of the transaction date.

Is this MANE Form 4 mainly a buy or a sell from the CEO’s perspective?

The Form 4 reflects a net sale position. While 3,452 shares were acquired through option exercise, the CEO reported selling 67,500 common shares, resulting in net shares disposed according to the transaction summary.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/18/2026 - 09:05 PM Accepted by SEC EDGAR 08/18/2026 - 09:04 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Waldman Reid Alexander

(Last) (First) (Middle)

C/O VERADERMICS, INCORPORATED

470 JAMES ST.

(Street)

NEW HAVEN CONNECTICUT 06513

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Veradermics, Inc [ MANE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/17/2026		M		3,452	A	$12.19	238,324	D
Common Stock	08/17/2026		S		11,527	D	$106.72(1)	226,797	D
Common Stock	08/17/2026		S		25,234	D	$107.53(2)	201,563	D
Common Stock	08/17/2026		S		27,490	D	$108.45(3)	174,073	D
Common Stock	08/17/2026		S		3,000	D	$109.38(4)	171,073	D
Common Stock	08/17/2026		S		249	D	$111.28	170,824	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$12.19	08/17/2026		M			3,452	(5)	12/12/2026	Common Stock	3,452	$0	0	D

Explanation of Responses:

1. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $106.07 to $107.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

2. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $107.00 to $108.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

3. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $108.00 to $108.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

4. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $109.02 to $109.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

5. This option is fully vested and exercisable as of the date hereof.

Remarks:

	/s/ Michael Greco, Attorney-in-Fact	08/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)